2015
DOI: 10.1111/jphp.12365
|View full text |Cite
|
Sign up to set email alerts
|

Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro–in-silico–in-vivo approach

Abstract: A predictive model to describe both IR and MR dosage forms containing furosemide was attained. Because sensitivity analysis of the model is able to identify key factors influencing the plasma profile, this in-vitro-in-silico-in-vivo approach could be a useful tool for facilitating formulation development of drug products.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
16
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 25 publications
(16 citation statements)
references
References 27 publications
0
16
0
Order By: Relevance
“…14 and Otsuka et al. 34 This could be explained by the fact that APIs were located inside the pores and surface area was occupied with their molecules. 35,36…”
Section: Resultsmentioning
confidence: 99%
“…14 and Otsuka et al. 34 This could be explained by the fact that APIs were located inside the pores and surface area was occupied with their molecules. 35,36…”
Section: Resultsmentioning
confidence: 99%
“…Various other PBPK models of probenecid and furosemide with different applications have been published previously (33)(34)(35)(36)(37)(38). For probenecid, three PBPK models are available describing DDIs with drugs that are OAT substrates.…”
Section: Discussionmentioning
confidence: 99%
“…However, none of these analyses considered the probenecidfurosemide DDI or extended the model to include UGT1A9, MRP4 or OATP1B1 inhibition (33)(34)(35). The previously developed furosemide PBPK models were not built or evaluated for use in DDI prediction (36)(37)(38).…”
Section: Discussionmentioning
confidence: 99%
“…After construction of a model, the program calculates the values of each variable in the model at each successive time increment using a numerical integration using Euler’s or a Runge-Kutta method 24 . STELLA ® has been used effectively to construct a variety of pharmaceutically-related simulation models for: pharmacokinetics of orally administered drugs 2534 , ocular pharmacokinetics 35 , performance of sustained release dosage forms 36,37 , prodrug performance 38 , and gene expression 39 . The STELLA simulation model described here was used to simulate the permeation (dissolution followed by diffusion through the membrane) of a drug from respirable size particles of two anti-tubercular drugs, moxifloxacin and ethionamide, that have different aqueous solubilities.…”
Section: Introductionmentioning
confidence: 99%